2024-11-05 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

**1. Performance Comparison with S&P 500 (VOO)**

Eli Lilly and Co (LLY) is a pharmaceutical company that develops and manufactures a wide range of medicines. The company has significantly outperformed the S&P 500 (VOO) over the past period.  LLY's cumulative return is 774.98%, while the S&P 500's is 131.78%. This leads to a **current divergence of 643.2**, which represents the difference between LLY's cumulative return and the S&P 500's cumulative return.  The **relative divergence is 80.22%**, meaning LLY's performance currently sits at the 80.22nd percentile of its historical performance relative to the S&P 500. 

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|-----|-------|------|
| 2015 | 19.1% | 13.8% | 18.8% | 1.0 |
| 2016 | -13.8% | 19.2% | -24.7% | 0.8 |
| 2017 | 12.5% | 10.1% | -6.3% | 0.5 |
| 2018 | 40.5% | 14.7% | 51.9% | 0.8 |
| 2019 | 17.9% | 17.2% | -13.1% | 0.7 |
| 2020 | 41.5% | 22.1% | 22.2% | 0.7 |
| 2021 | 127.8% | 18.6% | 85.8% | 0.5 |
| 2022 | 96.7% | 13.5% | 142.9% | 0.5 |
| 2023 | 225.5% | 14.7% | 190.1% | 0.4 |
| 2024 | 215.4% | 18.7% | 180.2% | 0.9 |

The analysis shows LLY's consistent positive Alpha across most years, indicating its outperformance compared to the market. The Beta values are mostly below 1, suggesting LLY is less volatile than the overall market.

**2. Recent Price Movements:**

* Last-market price: 808.35
* Closing price: 818.93
* 5-day moving average: 858.93
* 20-day moving average: 898.31
* 60-day moving average: 913.13

The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting a downward trend in the short term. 

**3. Technical Indicators:**

* RSI: 13.25
* PPO: -1.08
* Delta_Previous_Relative_Divergence: -9.05 (-)
* Expected Return: 97.64%

The RSI value is significantly below 30, suggesting the stock is oversold. The PPO is negative, further indicating bearish momentum. The negative Delta_Previous_Relative_Divergence suggests a recent short-term decline. The expected return of 97.64% indicates a potential high long-term upside, especially considering the current oversold conditions.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-30 | 1.08 | $11.44 B |
| 2024-08-08 | 3.29 | $11.30 B |
| 2024-04-30 | 2.49 | $8.77 B |
| 2023-11-02 | -0.06 | $9.50 B |
| 2024-10-30 | -0.06 | $9.50 B |

The most recent earnings report (2024-10-30) showed an EPS of 1.08, exceeding analyst estimates by 0.18. This demonstrates a positive earnings surprise and reflects the company's strong financial performance. Revenue also exceeded expectations, reaching $11.44B. 

**5. Financial Data:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $11.44B | 81.02% |
| 2024-06-30 | $11.30B | 80.80% |
| 2024-03-31 | $8.77B | 80.91% |
| 2023-12-31 | $9.35B | 80.88% |
| 2023-09-30 | $9.50B | 80.42% |

Lilly continues to demonstrate strong revenue growth and healthy profit margins. The company's core business remains stable, with continued growth in key therapeutic areas like diabetes and oncology.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $14.24B | 6.81% |
| 2024-06-30 | $13.56B | 21.88% |
| 2024-03-31 | $12.81B | 17.51% |
| 2023-12-31 | $10.77B | 20.33% |
| 2023-09-30 | $11.22B | -0.51% |

While there are some fluctuations in ROE, overall the company has maintained a solid financial position with strong equity levels. This demonstrates its financial strength and ability to invest in future growth initiatives.

**6. Recent News and Developments:**

* **Earnings Release:** The most recent earnings report on 2024-10-30 showed strong revenue and EPS growth, exceeding analyst expectations.
* **Market Outlook:** Many analysts are optimistic about Lilly's future prospects, citing the company's strong product portfolio, expanding market reach, and pipeline of new drugs. 
* **Analyst Opinions:** According to FINBOLD, the average analyst rating for LLY is "Buy," with a price target of $980. This suggests significant potential for future upside. 

**7. Overall Analysis:**

Eli Lilly and Co (LLY) is a strong, financially sound company with a solid track record of growth and profitability. Despite the current stock price decline, the company's fundamentals remain strong, supported by its strong product portfolio, expanding market reach, and pipeline of new drugs. The oversold condition and high expected return suggest significant potential for future upside.  Considering LLY's consistent outperformance compared to the market, its strong financial position, and positive market outlook, the stock presents a compelling investment opportunity for long-term investors.

**8. Recommendation:**

Based on the current analysis, LLY appears to be a good investment option for long-term investors who are comfortable with some short-term volatility. The company's strong fundamentals, positive market outlook, and oversold condition create a favorable investment environment.  LLY's high expected return suggests potential for significant capital appreciation over the long term.

This is not financial advice, and investors should conduct their own research before making any investment decisions. 
